<h4>Background</h4>Dual antiplatelet therapy is essential for managing ST-elevation myocardial infarction (STEMI); however, the optimal choice of P2Y12 inhibitor in patients with thrombocytosis remains unclear. The gene discussed is P2RY12; the disease is Thrombocytosis.